Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.
By J. Gérard, D. Azria, S. Gourgou-Bourgade, I. Martel-Laffay, C. Hennequin, P. Etienne, V. Vendrely, E. François, G. de La Roche, O. Bouché and 10 more. Journal of Clinical Oncology, 2010
731 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/f13a12c56f2b471bc1b5724576431ead09e8dcdf
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. (2012, positive): “The use of long-course preoperative chemoradiotherapy with different chemotherapeutic and biologic agents has been investigated with the aim of further improving local control and survival.(7,8) Although both short-course preoperative radiotherapy and longcourse preoperative chemoradiotherapy have b”
- ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. (2012, result): “Despite early promising results for 5-FU/oxaliplatin or capecitabine/oxaliplatin, local complete pathological response (pCR) was not increased compared with FU alone in the STAR-01, ACCORD 12/ 0405-Prodige 2, and NSABP R-04 [61–63].”